The versatility of mRNA has broadened its applications in mRNA vaccines, CRISPR gene editing therapeutics, and
protein replacement therapies. Conventional mRNA is associated with low stability and high immunogenicity.
However, mRNA synthesized by in vitro transcription (IVT) containing optimized structural elements shows
enhanced stability and greatly lowered immunogenicity.
GenScript provides a comprehensive portfolio of IVT mRNA reagents including proprietary capping enzymes and
other essential enzymes. The IVT mRNA reagents come with reliable performance and stringent quality controls to
provide complete support for mRNA-related research and production.